The expression of Bcl-XL, Bcl-XS and p27Kip1 in topotecan-induced apoptosis in hepatoblastoma HepG2 cell line

Cancer Investigation

Volumn 26, Issue 5, 2008, Pages 456-463

  Zhang, Jun ^a   Cheng, Chao ^b   He, Chuang Long ^b   Zhou, Yu Jian ^a   Cao, Yang ^b  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b CHONGQING UNIVERSITY   (China)

Author keywords

Apoptosis; HepG2 cells; p27Kip1; Topotecan

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; PROTEIN BCL XL; PROTEIN BCL XS; PROTEIN DERIVATIVE; RNA; SMALL INTERFERING RNA; TOPOTECAN;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CHROMATIN; CONTROLLED STUDY; CYTOPLASM; CYTOTOXICITY; DNA DAMAGE; DOWN REGULATION; FLOW CYTOMETRY; GENETIC TRANSFECTION; HEPATOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; INTERPHASE; NITROBLUE TETRAZOLIUM TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; TRANSMISSION ELECTRON MICROSCOPY; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; CELL CYCLE; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; DNA TOPOISOMERASES, TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FLOW CYTOMETRY; HEPATOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITORY CONCENTRATION 50; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; MICROSCOPY, ELECTRON, TRANSMISSION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TOPOTECAN; TRANSFECTION;

EID: 45949108557     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900701683968     Document Type: Article

References (22)

1. Herben, V.M.; ten Bokkel Huinink, W.W.; Beijnen, J.H. Clinical pharmacokinetics of topotecan [J]. Clin Pharmacokinet 1996, 31, 85-102.
2. Iyer, L.; Ratain, M.J. Clinical pharmacology of camptothecins [J]. Cancer Chemother Pharmacol 1998, 42, S31-43.
3. Emerson, D.L.; Besterman, J.M.; Brown, H.R.S.; Evans, M.G.; Leitner, P.P.; Luzzio, M.J.; Shaffer, J.E.; Sternbach, D.D.; Uehling D, Vuong A. In vivo antitumor of two new seven-substituted water-soluble camptothecin analogues [J]. Cancer Res 1995, 55(3), 603-609.
4. Hsiang, Y.H.; Liu, L.F. Indentification of mammalian DNA topoisomerase ?as an intracellular target of the anticancer drug camptothecin [J]. Cancer Res 1988, 48(7), 1722-1729.
5. Liu, L.F. DNA topoisomerase poisons as antitumor agent [J]. Ann Rev Biochem 1989, 58, 351-375.
6. Downes, C.S.; Johnson, R.T. DNA topoisomerases and DNA repair [J]. Bioessays 1988, 8(6), 179-184.
7. Roca J. The mechanisms of DNA topoisomerase [J]. Trends Biochem Sci 1995, 20(4), 156-160.
8. Wang, J.C. DNA topoisomerase [J]. Ann Rev Biochem 1996, 65, 635-692.
9. Pommier, Y.; Leteurtre, F.; Fesen, M.R.; Fujimori, A.; Bertrand, R.; Solary, E.; Kohlhagen, G.; Kohn, K.W. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitor [J]. Cancer Investig 1994, 12(5), 530-542.
10. Liu, L.F.; Duann P, Lin, C.T.; D'Arpa P, Wu J. Mechanism of action of camptothecin [J]. Ann NY Acad Sci 1996, 803, 44-49.
11. Uckun, F.M.; Stewart, C.F.; Reaman G, Chelstrom, L.M.; Jin J, Chandan-Langlie M, Waddick, K.G.; White J, Evans, W.E. In vitro and in vivo activity of topotecan against human B-lineage acute lymphoblastic leukemia cells [J]. Blood 1995, 85(10), 2817-2828.
12. Fu, Q.; Kim, S.W.; Chen, H.X.; Grill, S.; Cheng, Y.C. Degradation of topoisomerase I induced by topoisomerase I inhibitors is dependent on inhibitor structure but independent of cell death [J]. Molecular Pharmacol 1999, 55(4), 677-683.
13. Keshelava, N.; Groshen, S.; Reynolds, C.P. Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines [J]. Cancer Chemother Pharmacol 2000, 45(1), 1-8.
14. Silber, R.; Degar, B.; Costin, D.; Newcomb, E.W.; Mani, M.; Rosenberg, C.R.; Morse, L.; Drygas, J.C.; Canellakis, Z.N.; Potmesil, M. Chemosensitivity of lymphocytes from patients with B-cell chrsonic lymphocytic leukemia to chlorambucil, fludarabine, and camptothecin analogs [J]. Blood 1994, 84(10), 3440-3446.
15. Mitsui, I.; Kumazawa, E.; Hirota, Y.; Aonuma, M.; Sugimori, M.; Ohsuki, S.; Uoto, K.; Ejima, A.; Terasawa, H.; Sato, K. A new water-soluble camptothecin derivative Dx-8951f exhibits potent antitumor activity against human tumors in vitro and in vivo [J]. Jpn J Cancer Res 1995, 86(8), 776-782.
16. Plumb, J.A.; Milroy, R.; Kaye, S.B. Effects of the PH dependence of 3-(4,5-dimethyl-2-yl)-2,5-diphenyl-tetrazolium-bromide-formazan adsorption on chemosensitivity determined by a novel tetrazolium-based assay [J]. Cancer Res 1989, 49(16), 4435-4440.
17. Takehara, T.; Liu, X.; Fujimoto, J.; Friedman, S.L.; Takahashi, H. Expression and role of Bcl-xL in human hepatocellular carcinomas [J]. Hepatol 2001, 34(1), 55-61.
18. Emanuele, S.; Calvaruso, G.; Lauricella, M.; Giuliano, M.; Bellavia, G.; D'Anneo, A.; Vento, R.; Tesoriere, G. Apoptosis induced in hepatoblastoma HepG2 cells by the proteasome inhibitor MG132 is associated with hydrogen peroxide production, expression of Bcl-XS and activation of caspase-3 [J]. Int J Oncol 2002, 21(4), 857-65.
19. Kim, H.; Rafiuddin-Shah, M.; Tu, H.C.; Jeffers, J.R.; Zambetti, G.P.; Hsieh, J.J.; Cheng, E.H. Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies [J]. Nat Cell Biol 2006, 8(12), 1348-58.
20. Lazou, A.; Iliodromitis, E.K.; Cieslak, D.; Voskarides, K.; Mousikos, S.; Bofilis, E.; Kremastinos, D.T. Ischemic but not mechanical preconditioning attenuates ischemia/reperfusion induced myocardial apoptosis in anaesthetized rabbits: The role of Bcl-2 family proteins and ERK1/2 [J]. Apoptosis 2006, 11(12), 2195-204.
21. Luo, D.; Cheng, S.C.; Xie, H.; Xie, Y. Effects of Bcl-2 and Bcl-XL protein levels on chemoresistance of hepatoblastoma HepG2 cell line [J]. Biochem Cell Biol 2000, 78(2), 119-26.
22. Li, W.; Sanki, A.; Karim, R.Z.; Thompson, J.F.; Soon Lee. C.; Zhuang, L.; McCarthy, S.W.; Scolyer, R.A. The role of cell cycle regulatory proteins in the pathogenesis of melanoma [J]. Pathol 2006, 38(4), 287-301.